Combined modality therapy with TRAIL or agonistic death receptor antibodies

Cancer Biology and Therapy

Volumn 11, Issue 5, 2011, Pages 431-449

  Amm, Hope M ^a   Oliver, Patsy G ^b   Lee, Choo Hyung ^c   Li, Yufeng ^c   Buchsbaum, Donald J ^b  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Apoptosis; Cancer therapy; Combination chemotherapy; Death receptor 4; Death receptor 5; Death receptor antibodies; TRAIL

Indexed keywords

APOMAB; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CONATUMUMAB; CYCLOHEXIMIDE; DACTINOMYCIN; DEATH RECEPTOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLICE INHIBITORY PROTEIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; RECEPTOR ANTIBODY; TIGATUZUMAB; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DRUG ACTIVITY; GENE TARGETING; HUMAN; LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; COMBINED MODALITY THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79952336885     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.5.14671     Document Type: Review

References (200)

1. Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62.
2. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157-63. (Pubitemid 29068521)
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
4. Pitti R, Marsters S, Ruppert S, Donahue C, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90. (Pubitemid 26175834)
5. Bouralexis S, Findlay DM, Evdokiou A. Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 2005; 10:35-51. (Pubitemid 40575634)
6. Boehrer S, Nowak D, Hoelzer D, Mitrou P, Chow K. The molecular biology of TRAIL-mediated signaling and its potential therapeutic exploitation in hematopoietic malignancies. Curr Med Chem 2006; 13:2091-100. (Pubitemid 44132601)
7. Wassenaar T, Quax W, Mark A. The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: a molecular dynamics study. Proteins 2008; 70:333-43.
8. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29:4752-65.
9. Ashkenazi A, Dixit V. Death receptors: signaling and modulation. Science 1998; 281:1305-8. (Pubitemid 28406815)
10. Ruiz de Almodóvar C, López-Rivas A, Redondo J, Rodríguez A. Transcriptional regulation of the TRAIL-R3 gene. Vitam Horm 2004; 67:51-63.
11. Pan G, O'Rourke K, Chinnaiyan A, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3. (Pubitemid 27161256)
12. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20. (Pubitemid 27438841)
13. Sheridan J, Marsters S, Pitti R, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-21. (Pubitemid 27366733)
14. Schneider P, Bodmer J, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997; 416:329-34. (Pubitemid 27475391)
15. Walczak H, Degli-Esposti M, Johnson R, Smolak P, Waugh J, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-97. (Pubitemid 27380146)
16. Pan G, Ni J, Wei Y, Yu G, Gentz R, Dixit V. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-8. (Pubitemid 27366732)
17. Degli-Esposti M, Dougall W, Smolak P, Waugh J, Smith C, Goodwin R. The novel receptor TRAIL-R4 induces NFkappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20. (Pubitemid 28064894)
18. Marsters S, Sheridan J, Pitti R, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7:1003-6. (Pubitemid 28017080)
19. Harper N, Farrow S, Kaptein A, Cohen G, MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NFkappaB activation by inhibition of apical caspases. J Biol Chem 2001; 276:34743-52.
20. Cha S, Song Y, Oh B. Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex. Vitam Horm 2004; 67:1-17. (Pubitemid 39753657)
21. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7. (Pubitemid 28319153)
22. Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998; 273:5117-23. (Pubitemid 28108672)
23. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy M, Deen K, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275:23319-25. (Pubitemid 30646233)
24. Cassatella M, Huber V, Calzetti F, Margotto D, Tamassia N, Peri G, et al. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J Leukoc Biol 2006; 79:123-32. (Pubitemid 43054257)
25. Sato K, Hida S, Takayanagi H, Yokochi T, Kayagaki N, Takeda K, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFNalpha/beta. Eur J Immunol 2001; 31:3138-46. (Pubitemid 33100505)
26. Griffith T, Wiley S, Kubin M, Sedger L, Maliszewski C, Fanger N. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343-54.
27. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NFκB pathway. Immunity 1997; 7:821-30. (Pubitemid 28064895)
28. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: Lack of TRAIL-induced apoptosis in FADD-deficient mouse embryonic fibroblasts. J Biol Chem 2000; 275:25065-8.
29. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001; 276:46639-46.
30. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001; 20:2122-33. (Pubitemid 32424006)
31. Bodmer J, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2:241-3.
32. Thomas L, Henson A, Reed J, Salsbury F, Thorburn A. Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. J Biol Chem 2004; 279:32780-5. (Pubitemid 39014737)
33. Muzio M, Stockwell B, Stennicke H, Salvesen G, Dixit V. An induced proximity model for caspase-8 activation. J Biol Chem 1998; 273:2926-30. (Pubitemid 28133943)
34. Hao C, Song J, Vilimanovich U, Kneteman N. Modulation of TRAIL signaling complex. Vitam Horm 2004; 67:81-99. (Pubitemid 39753661)
35. Scorrano L, Korsmeyer S. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 2003; 304:437-44.
36. Kandasamy K, Srinivasula S, Alnemri E, Thompson C, Korsmeyer S, Bryant J, et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 2003; 63:1712-21.
37. Wu X, Ogawa O, Kakehi Y. TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 2004; 67:365-83. (Pubitemid 39753671)
38. Jo M, Kim T, Seol D, Esplen J, Dorko K, Billiar T, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564-7. (Pubitemid 30305907)
39. Kelley S, Harris L, Xie D, Deforge L, Totpal K, Bussiere J, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics and safety. J Pharmacol Exp Ther 2001; 299:31-8. (Pubitemid 32905115)
40. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, et al. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006; 24:124.
41. Fulda S, Debatin K. Modulation of TRAIL signaling for cancer therapy. Vitam Horm 2004; 67:275-90. (Pubitemid 39753668)
42. Buchsbaum D, Zhou T, Lobuglio A. TRAIL receptor-targeted therapy. Future Oncol 2006; 2:493-508. (Pubitemid 44304608)
43. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, et al. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008; 19:1060-7. (Pubitemid 351796330)
44. Saleh MN, Percent I, Wood TE, Posey J, III, Shah J, Carlisle R, et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. J Clin Oncol 2008; 26:3537.
45. Wiezorek J, holland P, Graes J. death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16:1701-8.
46. LoRusso P, Hong D, Heath E, Kurzrock R, Wang D, Hsu M, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 2007; 25:3534.
47. Buchsbaum D, Zhou T, Grizzle W, Oliver P, Hammond C, Zhang S, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003; 9:3731-41. (Pubitemid 37169242)
48. Amm HM, Oliver PG, Buchsbaum DJ. XIAP siRNA or chemotherapy increase apoptosis of breast cancer cells treated with TRA-8 anti-DR5 antibody. AACR Annual Meeting. Washington, DC: Proc Am Assoc Cancer Res 2006; 41.
49. Straughn JM Jr, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, et al. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol 2006; 101:46-54.
50. Estes J, Oliver P, Straughn JJ, Zhou T, Wang W, Grizzle W, et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007; 105:291-8. (Pubitemid 46590329)
51. DeRosier L, Buchsbaum D, Oliver P, Huang Z, Sellers J, Grizzle W, et al. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007; 13:5535-43.
52. Derosier L, Vickers S, Zinn K, Huang Z, Wang W, Grizzle W, et al. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007; 6:3198-207.
53. Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, Buchsbaum DJ. Enhancement of glioma radiation therapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 2008; 71:507-16. (Pubitemid 351636198)
54. Oliver P, LoBuglio A, Zinn K, Kim H, Nan L, Zhou T, et al. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 2008; 14:2180-9. (Pubitemid 351551131)
55. Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 2008; 14:7733-40.
56. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br J Cancer 2005; 92:1430-41. (Pubitemid 40705010)
57. Marini P, Denzinger S, Schiller D, Kauder S, Welz S, Humphreys R, et al. Combined treatment of colorectal tumors with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006; 25:5145-54. (Pubitemid 44285983)
58. Georgakis G, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005; 130:501-10. (Pubitemid 43899752)
59. Plummer R, Attard G, Pacey S, Li L, Razak A, Perrett R, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007; 13:6187-94. (Pubitemid 350075080)
60. Tolcher A, Mita M, Meropol N, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25:1390-5. (Pubitemid 46706887)
61. Greco F, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008; 61:82-90.
62. th ASCO Annual Meeting. Chicago, IL: J Clin Oncol 2010; 18.
63. Ashkenazi A, Herbst R. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 2008; 118:1979-90. (Pubitemid 351872316)
64. Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J, et al. A phase Ib safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. 43rd ASCO Annual Meeting: J Clin Oncol 2007; 8078.
65. th ASCO Annual Meeting. Chicago, IL: J Clin Oncol 2008; 3540.
66. Sikic BI, Wakelee HA, Mehren Mv, Lewis N, Calvert AH, Plummer ER, et al. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. J Clin Oncol 2007; 25:14006.
67. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12:228-37. (Pubitemid 40315182)
68. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59:734-41. (Pubitemid 29076075)
69. Jang Y, Park K, Chung H, Kim H. Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. Cancer Lett 2003; 194:107-17. (Pubitemid 36428890)
70. Ozawa F, Friess H, Kleeff J, Xu Z, Zimmermann A, Sheikh M, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 2001; 163:71-81. (Pubitemid 32121832)
71. Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, et al. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery 2005; 138:71-7. (Pubitemid 40933774)
72. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000; 32:482-90.
73. Wu X, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y, et al. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003; 104:409-17. (Pubitemid 36323909)
74. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20:205-12. (Pubitemid 30002562)
75. Wu G, Burns T, McDonald Er, Jiang W, Meng R, Krantz I, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17:141-3.
76. Wang S, El-Deiry W. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci USA 2003; 100:15095-100. (Pubitemid 37518022)
77. Wagner K, King F, Nomoto K, Knee D, Hampton G, Nasoff M, et al. Activation and suppression of the TRAIL death-receptor pathway in chemotherapy sensitive and resistant follicular lymphoma cells. Cancer Biol Ther 2003; 2:534-40.
78. Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert TL, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 2000; 97:1754-9. (Pubitemid 30118515)
79. Shankar S, Singh T, Chen X, Thakkar H, Firnin J, Srivastava R. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004; 24:1133-40.
80. Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000; 19:1735-43. (Pubitemid 30200979)
81. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res 2004; 64:5078-83. (Pubitemid 39006522)
82. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett 2001; 507:381-5. (Pubitemid 33030270)
83. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NFkappaB in response to etoposide treatment. Apoptosis 2008; 13:756-70.
84. Ravi R, Bedi G, Engstrom L, Zeng Q, Mookerjee B, Gélinas C, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NFkappaB. Nat Cell Biol 2001; 3:409-16. (Pubitemid 32288449)
85. Baritaki S, Huerta-Yepez S, Sakai T, Spandidos DA, Bonavida B. Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: upregulation of DR5 and inhibition of Yin Yang 1. Mol Cancer Ther 2007; 6:1387-99. (Pubitemid 46712002)
86. Baritaki S, Suzuki E, Umezawa K, Spandidos DA, Berenson J, Daniels TR, et al. Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol 2008; 180:6199-210.
87. Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, et al. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 2009; 20:39-52.
88. Yoshida T, Sakai T. Promoter of TRAIL-R2 gene. Vitam Horm 2004; 67:35-49. (Pubitemid 39753659)
89. Kim YH, Park JW, Lee JY, Kwon TK. Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells. Carcinogenesis 2004; 25:1813-20. (Pubitemid 39405899)
90. VanOosten R, Moore J, Karacay B, Griffith T. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biol Ther 2005; 4:1104-12. (Pubitemid 41598565)
91. Dumitru CA, Carpinteiro A, Trarbach T, Hengge UR, Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 2007; 12:1533-41. (Pubitemid 46988288)
92. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J Biol Chem 2007; 282:12831-41. (Pubitemid 47100635)
93. Wagner K, Punnoose E, Januario T, Lawrence D, Pitti R, Lancaster K, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007; 13:1070-7. (Pubitemid 47517508)
94. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280:2205-12.
95. Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y. Predominant antitumor effects by fully human anti-TRAIL-receptor2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo. Neuro Oncol 2010; 12:687-700.
96. Stadel D, Mohr A, Ref C, Macfarlane M, Zhou S, Humphreys R, et al. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16:5734-49.
97. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12:773-82. (Pubitemid 40945984)
98. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Röder C, et al. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 2010; 88:729-40.
99. Roth W, Reed J. FLIP protein and TRAIL-induced apoptosis. Vitam Horm 2004; 67:189-206. (Pubitemid 39753664)
100. Ryu B, Lee M, Chi S, Kim Y, Park J. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 2001; 194:15-9.
101. Griffith T, Chin W, Jackson G, Lynch D, Kubin M. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161:2833-40. (Pubitemid 28425704)
102. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005; 5:2.
103. Kim Y, Suh N, Sporn M, Reed J. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277:22320-9. (Pubitemid 34967199)
104. Suh W, Kim Y, Schimmer A, Kitada S, Minden M, Andreeff M, et al. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL. Leukemia 2003; 17:2122-9. (Pubitemid 37428377)
105. Hyer M, Croxton R, Krajewska M, Krajewski S, Kress C, Lu M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 2005; 65:4799-808. (Pubitemid 40740818)
106. Mitsiades N, Mitsiades C, Poulaki V, Anderson K, Treon S. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99:2162-71. (Pubitemid 34525502)
107. Zhang X, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59:2747-53. (Pubitemid 29269125)
108. Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123:168-74.
109. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir E, Yong V, et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 2001; 61:1162-70. (Pubitemid 32174439)
110. Cory S, Adams J. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-56. (Pubitemid 37328916)
111. Walensky L. BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13:1339-50. (Pubitemid 44057469)
112. Fulda S, Meyer E, Debatin K. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21:2283-94. (Pubitemid 34407288)
113. Sun S, Yue P, Zhou J, Wang Y, Choi Kim H, Lotan R, et al. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem Biophys Res Commun 2001; 280:788-97. (Pubitemid 32924499)
114. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin Cancer Res 2004; 10:8284-92. (Pubitemid 40053388)
115. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, Bayer E, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene 2000; 19:5477-86. (Pubitemid 32000915)
116. Han J, Goldstein L, Gastman B, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006; 281:10153-63. (Pubitemid 43864551)
117. Clohessy J, Zhuang J, de Boer J, Gil-Gómez G, Brady H. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 2006; 281:5750-9. (Pubitemid 43847674)
118. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk S, Farrugia D, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64:3517-24. (Pubitemid 38657926)
119. Mott J, Kobayashi S, Bronk S, Gores G. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 13:6133-40. (Pubitemid 47414372)
120. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8:274-81. (Pubitemid 34250106)
121. von Haefen C, Gillissen B, Hemmati PG, Wendt J, Guner D, Mrozek A, et al. Multidomain Bcl-2 homolog Bax but not Bak mediates synergistic induction of apoptosis by TRAIL and 5-FU through the mitochondrial apoptosis pathway. Oncogene 2004; 23:8320-32. (Pubitemid 39531843)
122. Wendt J, von Haefen C, Hemmati P, Belka C, Dörken B, Daniel PT. TRAIL sensitizes for ionizing irradiationinduced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 2005; 24:4052-64. (Pubitemid 40897052)
123. Han J, Goldstein L, Gastman B, Rabinovitz A, Wang G, Fang B, et al. Differential involvement of Bax and Bak in TRAIL-mediated apoptosis of leukemic T cells. Leukemia 2004; 18:1671-80. (Pubitemid 39386346)
124. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003; 63:4713-23. (Pubitemid 36951052)
125. Yin D, Zhou H, Kumagai T, Liu g, Ong J, Black K, et al. Proteasome inhibitors PS-341 causes cell growth arrest and apoptosis in human gliobastoma multiforme (GBM). Oncogene 2005; 24:344-54.
126. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis J, et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005; 4:781-6. (Pubitemid 41351180)
127. Hao J, Yu M, Liu F, Newland A, Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res 2004; 64:3607-16. (Pubitemid 38657939)
128. Chawla-Sarkar M, Bae S, Reu F, Jacobs B, Lindner D, Borden E. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11:915-23.
129. Yeow WS, Baras A, Chua A, Nguyen DM, Sehgal SS, Schrump DS, et al. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg 2006; 132:1356-62.
130. Song J, Kandasamy K, Kraft A. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008; 283:25003-13.
131. Huang S, Sinicrope F. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68:2944-51. (Pubitemid 351556295)
132. Vaux D, Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 2005; 6:287-97.
133. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-52. (Pubitemid 29095796)
134. Eckelman B, Salvesen G, Scott F. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7:988-94. (Pubitemid 44480512)
135. Amantana A, London C, Iversen P, Devi G. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 2004; 3:699-707. (Pubitemid 39193751)
136. Cummins J, Kohli M, Rago C, Kinzler K, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64:3006-8. (Pubitemid 38581397)
137. Li H, Niederkorn J, Neelam S, Alizadeh H. Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis. Arch Ophthalmol 2005; 123:654-61. (Pubitemid 40695514)
138. Ng C, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 2002; 53:286-99. (Pubitemid 35398499)
139. Roa W, Chen H, Fulton D, Gulavita S, Shaw A, Th'ng J, et al. X-linked inhibitor regulating TRAIL-induced apoptosis in chemoresistant human primary glioblastoma cells. Clin Invest Med 2003; 26:231-42.
140. Yang L, Cao Z, Yan H, Wood W. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res 2003; 63:6815-24. (Pubitemid 37322964)
141. Aggarwal B, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 2004; 67:453-83. (Pubitemid 39753674)
142. Rosato R, Dai Y, Almenara J, Maggio S, Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 2004; 18:1780-8. (Pubitemid 39530007)
143. Vogler M, Walczak H, Stadel D, Haas T, Genze F, Jovanovic M, et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res 2008; 68:7956-65.
144. Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 2007; 105:481-92. (Pubitemid 46590342)
145. Foster F, Owens T, Tanianis-Hughes J, Clarke R, Brennan K, Bundred N, et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 2009; 11:41.
146. Altieri D. Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem 2004; 92:656-63. (Pubitemid 44264257)
147. Griffith T, Kemp T. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis. Cancer Chemother Pharmacol 2003; 52:175-84. (Pubitemid 37204530)
148. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer J, et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280:6742-51. (Pubitemid 40341229)
149. Wajant H. TRAIL and NFkappaB signaling - a complex relationship. Vitam Horm 2004; 67:101-32. (Pubitemid 39753919)
150. Hu W, Johnson H, Shu H. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NFkappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999; 274:30603-10.
151. Chen X, Kandasamy K, Srivastava R. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003; 63:1059-66. (Pubitemid 36278439)
152. Kim Y, Schwabe R, Qian T, Lemasters J, Brenner D. TRAIL-mediated apoptosis requires NFkappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 2002; 36:1498-508. (Pubitemid 35403540)
153. Mitsiades C, Treon S, Mitsiades N, Shima Y, Richardson P, Schlossman R, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98:795-804.
154. Bai J, Sui J, Demirjian A, Vollmer CM Jr, Marasco W, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 2005; 65:2344-52. (Pubitemid 40490145)
155. Shigeno M, Nakao K, Ichikawa T, Suzuki K, Kawakami A, Abiru S, et al. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NFkappaB inactivation. Oncogene 2003; 22:1653-62. (Pubitemid 36408180)
156. Deeb D, Jiang H, Gao X, Hafner M, Wong H, Divine G, et al. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factorkappaB through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther 2004; 3:803-12. (Pubitemid 39193762)
157. Whang Y, Yuan X, Liu Y, Majumder S, Lewis T. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. Vitam Horm 2004; 67:409-26. (Pubitemid 39753672)
158. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9:667-76. (Pubitemid 40941196)
159. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20:6073-83. (Pubitemid 32955050)
160. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001; 276:10767-74. (Pubitemid 38089250)
161. Yuan X, Whang Y. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002; 21:319-27. (Pubitemid 34102140)
162. Nam S, Jung G, Hur G, Chung H, Kim W, Seol D, et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 2003; 94:1066-73. (Pubitemid 38035521)
163. Bortul R, Tazzari P, Cappellini A, Tabellini G, Billi A, Bareggi R, et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NFkappaB activation and cFLIP(L) upregulation. Leukemia 2003; 17:379-89.
164. Kandasamy K, Srivastava RK. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002; 62:4929-37. (Pubitemid 34984416)
165. Asakuma J, Sumitomo M, Asano T, Asano T, Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003; 63:1365-70. (Pubitemid 36348718)
166. Mitsiades C, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, et al. Activation of NFkappaB and upregulation of intracellular antiapoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21:5673-83. (Pubitemid 35333000)
167. Poulaki V, Mitsiades C, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras D, et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002; 161:643-54. (Pubitemid 36142173)
168. Gibson E, Henson E, Haney N, Villanueva J, Gibson S. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 2002; 62:488-96.
169. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, et al. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007; 67:1430-5. (Pubitemid 46383367)
170. waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J Biol Chem 2006; 281:34742-50.
171. Wang W, Kim S, El-Deiry W. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006; 103:11003-8. (Pubitemid 44148408)
172. Isakoff SJ, Leong C, Vidnovic N, DeYoung MP, Sgroim D, Goss PE, et al. p63/p73 expression mediates cisplatin sensitivity in a subset of triple-negative primary breast cancer: Implications for a new clinical trial. J Clin Oncol 2007; 25:10522.
173. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Valent A, Bénard J, et al. p73 functionally replaces p53 in Adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005; 116:860-9. (Pubitemid 41209191)
174. Weinmann L, Wischhusen J, Demma M, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2008; 15:718-29. (Pubitemid 351405077)
175. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, et al. Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 2008; 283:19665-77.
176. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy 2008; 4:940-3.
177. Hou W, Han J, Lu C, Goldstein LA, Rabinowich H. Autophagic degradation of active caspase-8: a cross-talk mechanism between autophagy and apoptosis. Autophagy 2010; 6:891-900.
178. Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci USA 2004; 101:3438-43. (Pubitemid 38338213)
179. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010; 6:322-9.
180. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010; 221:3-12.
181. Niu TK, Cheng Y, Ren X, Yang JM. Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS Lett 2010; 584:3519-24.
182. Turcotte S, Giaccia AJ. Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol 2010; 22:246-51.
183. Naka T, Sugamura K, Hylander B, Widmer M, Rustum Y, Repasky E. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 2002; 62:5800-6. (Pubitemid 35204738)
184. Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004; 64:4900-5. (Pubitemid 38924535)
185. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W, et al. Irradiation specifically sensitises solid tumor cell lines to TRAIL mediated apoptosis. BMC Cancer 2005; 5:5.
186. Shankar S, Singh T, Srivastava R. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004; 61:35-49. (Pubitemid 39095693)
187. Takahashi M, Yasui H, Ogura A, Asanuma T, Kubota N, Tsujitani M, et al. X irradiation combined with TNF alpha-related apoptosis-inducing ligand (TRAIL) reduces hypoxic regions of human gastric adenocarcinoma xenografts in SCID mice. J Radiat Res (Tokyo) 2008; 49:153-61. (Pubitemid 351468642)
188. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, et al. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 2008; 100:649-62.
189. Luster T, Carrell J, McCormick K, Sun D, Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther 2009; 8:292-302.
190. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri F, et al. The proteasome inhibitor PS-341 (bortezomib) upregulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite upregulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67:4981-8. (Pubitemid 46910207)
191. Chen K, Yeh P, Hsu C, Hsu C, Lu Y, Hsieh H, et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol-3-kinase/Akt pathway. J Biol Chem 2009; 284:11121-33.
192. Fulda S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr Cancer Drug Targets 2008; 8:132-40. (Pubitemid 351347249)
193. Gillespie S, Borrow J, Zhang X, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis 2006; 11:2251-65. (Pubitemid 44885400)
194. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss T, Gregor M, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006; 43:425-34.
195. Shankar S, Singh T, Fandy T, Luetrakul T, Ross D, Srivastava R. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005; 16:1125-38.
196. Vanoosten RL, Moore JM, Ludwig AT, Griffith TS. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005; 11:542-52. (Pubitemid 40353112)
197. Inoue S, MacFarlane M, Harper N, Wheat L, Dyer M, Cohen G. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)- induced apoptosis in lymphoid malignancies. Cell Death Differ 2004; 11:193-206.
198. Georgakis G, Li Y, Rassidakis G, Martinez-Valdez H, Medeiros L, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy- geldanamycin in Hodgkin's lymphoma cells downregulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006; 12:584-90. (Pubitemid 43166153)
199. Siegelin M, Habel A, Gaiser T. 17-AAG sensitized malignant glioma cells to death-receptor mediated apoptosis. Neurobiol Dis 2009; 33:243-9.
200. Ray S, Bucur O, Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005; 10:1411-8. (Pubitemid 43117685)